Merck Backs Alnylam’s RNAi Technology
Business Review Editor
Abstract
Merck and Alnylam Holding entered into multiyear research collaboration to develop new drugs using Alnylam’s RNA interference (RNAi) Technology.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.